| View |
|
DR-XY43773
|
CEFTAZIDIME (AS PENTAHYDRATE)
|
CEFTAMED
|
1g
|
Powder For Injection (Iv/Im)
|
ANTIBACTERIALS (CEPHALOSPORINS)
|
Hankook Korus Pharm. Co., Ltd.
|
Korea
|
Renewal
|
25 August 2024
|
02 October 2029
|
| View |
|
DR-XY43774
|
Betamethasone Valerate
|
None
|
1mg/ g
|
Topical Cream
|
Corticosteroid
|
DS COSMECEUTICAL MANUFACTURING LABORATORY
|
Philippines
|
Automatic Renewal
|
06 September 2021
|
02 October 2026
|
| View |
|
DR-XY43775
|
Betamethasone (as valerate)
|
None
|
1mg/g
|
CREAM
|
Corticosteroids
|
DS Cosmeceutical Manufacturing Laboratory
|
Philippines
|
Automatic Renewal
|
31 January 2022
|
13 March 2027
|
| View |
|
DR-XY43776
|
Azithromycin (as dihydrate)
|
Aztrozin
|
500mg
|
Powder For Iv Infusion
|
Antibacterial
|
Jiangsu Kingsley Pharmaceutical Co., Ltd.
|
China
|
Renewal
|
06 August 2024
|
02 October 2029
|
| View |
|
DR-XY43779
|
Afatinib (as dimaleate)
|
Giotrif
|
20 mg
|
Film-Coated Tablet
|
Antineoplastic Agent (Protein kinase inhibitor)
|
Boehringer Ingelheim Pharma GmbH & Co. KG
|
Germany
|
Renewal
|
11 August 2024
|
07 October 2029
|
| View |
|
DR-XY43780
|
Afatinib (as dimaleate)
|
Giotrif
|
30 mg
|
Film-Coated Tablet
|
Antineoplastic Agent (Protein kinase inhibitor)
|
Boehringer Ingelheim Pharma GmbH & Co. KG
|
Germany
|
Renewal
|
28 August 2024
|
07 October 2029
|
| View |
|
DR-XY43782
|
Afatinib (as dimaleate)
|
Giotrif
|
40 mg
|
Film-Coated Tablet
|
Antineoplastic Agent (Protein kinase inhibitor)
|
Boehringer Ingelheim Pharma GmbH & Co. KG
|
Germany
|
Renewal
|
11 August 2024
|
07 October 2029
|
| View |
|
DR-XY43786
|
Sodium Nitroprusside
|
Imatrop
|
50 mg
|
Lyophilized Powder for Injection (IV)
|
Antihypertensive (Nitroferricyanide derivative)
|
Gufic Biosciences Pvt. Ltd.
|
India
|
Renewal
|
25 August 2024
|
16 October 2029
|
| View |
|
DR-XY43790
|
Metoprolol Tartrate
|
Hypetor
|
50 mg
|
Film-Coated Tablet
|
Beta Adrenoceptor Blocker
|
Lloyd Laboratories, Inc.
|
Philippines
|
Renewal
|
29 June 2024
|
16 October 2029
|
| View |
|
DR-XY43791
|
Simvastatin
|
Corvastin
|
40mg
|
Film-Coated Tablet
|
Antihyperlipidemic
|
Aurochem Pharmaceuticals (India) Pvt., Ltd.
|
India
|
Renewal
|
12 October 2024
|
16 October 2029
|
| View |
|
DR-XY43801
|
Azithromycin (As Dihydrate)
|
Azik
|
250mg
|
Film-Coated Tablet
|
Antibacterial (Macrolide)
|
Kusum Healthcare Pvt. Ltd.
|
India
|
Automatic Renewal
|
12 August 2021
|
16 October 2026
|
| View |
|
DR-XY43811
|
Irbesartan
|
Unbranded
|
300 mg
|
Film-Coated Tablet
|
Angiotensin II Receptor Blocker
|
Lloyd Laboratories, Inc.
|
Philippines
|
Renewal
|
08 July 2024
|
27 October 2029
|
| View |
|
DR-XY43821
|
FLUMAZENIL
|
Anzenil
|
100 mcg/mL
|
Solution for Intravenous Infusion
|
Benzodiazepine-receptor Antagonist
|
Yichang Humanwell Pharmaceutical Co., Ltd.
|
China
|
Renewal
|
11 August 2024
|
29 October 2029
|
| View |
|
DR-XY43828
|
Potassium Chloride + Sodium Chloride
|
FLO CRS
|
180 mg/ 150 mg Sachets
|
Powder For Reconstitution
|
Nasal and Sinus Irrigation Decongestant
|
Interphil Laboratories, Inc.
|
Philippines
|
Renewal
|
27 March 2024
|
23 October 2029
|
| View |
DR-XY43829_PI_01.pdf
|
DR-XY43829
|
Canagliflozin (as hemihydrate)
|
Invokana
|
300 mg
|
Film-Coated Tablet
|
Sodium-glucose co-transporter 2 (SGLT2) Inhibitor
|
Janssen Cilag S.P.A.
|
Italy
|
Renewal
|
20 October 2024
|
23 October 2029
|
| View |
|
DR-XY4383
|
Phenylpropanolamine Hydrochloride + Paracetamol
|
Nasathera
|
25 mg/ 325 mg
|
Capsule
|
Nasal Decongestant (Sympathomimetic)- Analgesic/Antipyretic
|
Morishita-Seggs Pharmaceuticals, Inc.
|
Philippines
|
Automatic Renewal
|
09 November 2022
|
30 October 2027
|
| View |
DR-XY43830_PI_01.pdf
|
DR-XY43830
|
Canagliflozin (as hemihydrate)
|
Invokana
|
100 mg
|
Film-Coated Tablet
|
Sodium-glucose co-transporter 2 (SGLT2) Inhibitor
|
Janssen Cilag S.P.A.
|
Italy
|
Renewal
|
20 October 2024
|
23 October 2029
|
| View |
|
DR-XY43850
|
Enalapril Maleate
|
Enafril
|
10 mg
|
Tablet
|
Angiotensin Converting Enzyme Inhibitor
|
Nanjing Baijingyu Pharmaceutical Co., Ltd.
|
China
|
Renewal
|
12 August 2024
|
30 October 2029
|
| View |
DR-XY43852_PI_01.pdf
|
DR-XY43852
|
Crizotinib
|
Xalkori
|
250mg
|
Capsule
|
Tyrosine Kinase Inhibitor
|
Pfizer manufacturing Deutschland GmbH
|
Germany
|
Renewal
|
13 September 2024
|
30 October 2029
|
| View |
DR-XY43853_PI_01.pdf
|
DR-XY43853
|
Crizotinib
|
Xalkori
|
200 mg
|
Capsule
|
Tyrosine Kinase Inhibitor
|
Pfizer manufacturing Deutschland GmbH
|
Germany
|
Renewal
|
27 September 2024
|
30 October 2029
|